Table 2 Correlation between the clinicopathological features and 2-year progression-free survival in combined hepatocellular cholangiocarcinoma
| Variables | No. of patients |
Cumulative 2- year progression-free survival rate | P | HR (95% CI) | P |
|---|---|---|---|---|---|
| Age | |||||
| < 60 | 28 | 38.5% | 0.941 | ||
| ≧60 | 24 | 35.6% | |||
| Gender | |||||
| Male | 37 | 35.8% | 0.097 | ||
| Female | 15 | 59.3% | |||
| Hepatitis B | |||||
| Negative | 17 | 39.7% | 0.632 | ||
| Positive | 35 | 44.9% | |||
| Hepatitis C | |||||
| Negative | 36 | 42.5% | 0.747 | ||
| Positive | 16 | 41.5% | |||
| Liver cirrhosis | |||||
| No cirrhosis | 14 | 55.1% | 0.479 | ||
| Cirrhosis | 38 | 39.2% | |||
| DM | |||||
| Negative | 38 | 44.7% | 0.575 | ||
| Positive | 14 | 37.5% | |||
| Gall stone | |||||
| Negative | 47 | 45.2% | 0.178 | ||
| Positive | 5 | 20.0% | |||
| CEA | |||||
| ≤ 5 | 45 | 44.3% | 0.311 | ||
| > 5 | 7 | 34.3% | |||
| CA-199 | |||||
| ≤ 35 | 36 | 43.7% | 0.535 | ||
| > 35 | 16 | 19.3% | |||
| AFP | |||||
| ≤ 15 | 23 | 26.6% | 0.978 | ||
| > 15 | 29 | 43.5% | |||
| Histology grade | |||||
| Well or Moderate | 38 | 44.9% | 0.499 | ||
| Poorly | 14 | 40.8% | |||
| LVI | |||||
| Negative | 33 | 50.4% | 0.022* | ||
| Positive | 19 | 15.0% | |||
| PNI | |||||
| Negative | 46 | 44.1% | 0.377 | ||
| Positive | 6 | 33.3% | |||
| Surgical margin | |||||
| <10 mm | 35 | 35.4% | 0.746 | ||
| ≥ 10 mm | 17 | 41.6% | |||
| T stage | |||||
| TI-II | 42 | 52.3% | < 0.001* | 8.004 (2.869-22.336) | < 0.001* |
| TIII-IV | 10 | 0% | |||
| N stage | |||||
| Negative | 49 | 43.3% | 0.223 | 4.701 (0.952-23.203) | 0.057 |
| Positive | 3 | 33.3% | |||
| AJCC staging | |||||
| I-II | 40 | 53.2% | < 0.001* | ||
| III-IV | 12 | 8.3% | |||
| Midkine expression | |||||
| Negative | 30 | 60.5% | < 0.001* | 4.238 (1.900-9.449) | < 0.001* |
| Positive | 22 | 8.5% | |||